You just read:

Eli Lilly's Emgality is Perceived as Increasingly Competitive with Amgen/Novartis' Aimovig and Teva's Ajovy in the US Migraine Prevention Market, as the Anti-CGRP Brand Pulls Ahead on Payer Approval Ease and Overall Prescriber Satisfaction

News provided by

Spherix Global Insights

Jul 02, 2019, 08:00 ET